Compare VOXR & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VOXR | TENX |
|---|---|---|
| Founded | 2014 | 1967 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 308.7M | 317.8M |
| IPO Year | 2022 | 2001 |
| Metric | VOXR | TENX |
|---|---|---|
| Price | $4.16 | $16.07 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $6.90 | ★ $29.67 |
| AVG Volume (30 Days) | 549.4K | ★ 1.4M |
| Earning Date | 05-08-2026 | 05-15-2026 |
| Dividend Yield | ★ 1.01% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $60.51 | N/A |
| Revenue Next Year | $44.51 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.13 | $5.77 |
| 52 Week High | $6.70 | $19.40 |
| Indicator | VOXR | TENX |
|---|---|---|
| Relative Strength Index (RSI) | 29.26 | 58.40 |
| Support Level | $3.86 | $12.84 |
| Resistance Level | $4.36 | $16.35 |
| Average True Range (ATR) | 0.21 | 1.28 |
| MACD | -0.02 | -0.07 |
| Stochastic Oscillator | 1.57 | 48.37 |
Vox Royalty Corp is a returns-focused mining royalty and streaming company. It holds a diversified portfolio of several royalties and streams, including producing and development stage assets, with primary exposure to gold and select industrial metals across top-tier mining jurisdictions. Vox is organized into two operating segments, consisting of acquiring and managing royalty interests; and acquiring and managing streams and other interests. Maximum revenue is generated from its Royalty Interests segment. The majority of the company's portfolio of royalty, streams, and other interests by asset count is located in Australia, Canada, and the United States, of which the maximum revenue is derived from its assets in Australia.
Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.